Results 11 to 20 of about 303,943 (292)
Slowing Progression in CKD [PDF]
Clinical Journal of the American Society of Nephrology, 2021 There is a recognized large global burden of CKD ([1][1]). With the projected rise in prevalence of diabetes in coming years, that burden may indeed increase. Thus, the need for therapies to slow the progression of CKD, and its attendant comorbidities, is critical.
Kathryn, Larmour, Adeera, Levin
openaire +2 more sources
Phosphate, Microbiota and CKD [PDF]
Nutrients, 2021 Phosphate is a key uremic toxin associated with adverse outcomes. As chronic kidney disease (CKD) progresses, the kidney capacity to excrete excess dietary phosphate decreases, triggering compensatory endocrine responses that drive CKD-mineral and bone disorder (CKD-MBD).
Chiara Favero +8 more
openaire +3 more sources
Nephrology Dialysis Transplantation, 2014 International ...
J. Fernandes +125 more
openaire +3 more sources
Kidney International Reports, 2020 Constipation is one of the most common gastrointestinal disorders among patients with chronic kidney disease (CKD) partly because of their sedentary lifestyle, low fiber and fluid intake, concomitant medications (e.g., phosphate binders), and multiple comorbidities (e.g., diabetes).
Keiichi Sumida +2 more
openaire +3 more sources
Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study [PDF]
Kidney360, 2022 Key Points The CKD-PGX study assessed the feasibility of pharmacogenomic testing for a panel of antihypertensive agent efficacy predictors.
Michael T. Eadon +11 more
openaire +2 more sources
Adipokines protecting CKD [PDF]
Nephrology Dialysis Transplantation, 2013 Increasing incidence of chronic kidney disease (CKD) which leads to end-stage renal disease (ESRD) is one of the major health issues in the modern world and requires novel strategies for treatment. Adipose tissue has been recognized to have endocrine function and secretes a variety of hormones called adipokines.
Satoshi, Miyamoto, Kumar, Sharma
openaire +2 more sources
Clinical Journal of the American Society of Nephrology, 2019 In general, nephrologists give little thought to contraception, leaving this task to other practitioners, but the significant risks associated with drugs routinely prescribed to treat kidney disease; the potential for pregnancy-associated adverse outcomes in women with CKD; and the effect ...
Anna, Burgner, Michelle A, Hladunewich
openaire +2 more sources
Arthritis Research & Therapy, 2020 Objectives Histone deacetylase (HDAC) 6 promotes inflammation. We investigated the anti-arthritic effects of CKD-506, a novel HDAC6 inhibitor, in vitro and in a murine model of arthritis as a novel treatment option for rheumatoid arthritis (RA).
Jin Kyun Park +11 more
doaj +1 more source
Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD) [PDF]
Pediatric Nephrology, 2009 Recent advances in our understanding of the excess mortality of chronic kidney disease (CKD) due to cardiovascular complications, obtained through observational studies, demonstrate that vascular calcification and hyperphosphatemia are major cardiovascular risk factors.
Keith A, Hruska +4 more
openaire +2 more sources
Bioavailability of the Common Cold Medicines in Jellies for Oral Administration
Pharmaceutics, 2020 Jellies for oral administration have been suggested as alternative dosage forms to conventional tablets for improved palatability and compliances for pediatric and geriatric patients.
Ki Hyun Kim, Minju Jun, Mi-Kyung Lee
doaj +1 more source